GT201500295A - Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado - Google Patents
Aglomerados respirables de partículas de vehículo porosas y fármaco micronizadoInfo
- Publication number
- GT201500295A GT201500295A GT201500295A GT201500295A GT201500295A GT 201500295 A GT201500295 A GT 201500295A GT 201500295 A GT201500295 A GT 201500295A GT 201500295 A GT201500295 A GT 201500295A GT 201500295 A GT201500295 A GT 201500295A
- Authority
- GT
- Guatemala
- Prior art keywords
- breathable
- aglomerates
- active agent
- porous
- particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784842P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201500295A true GT201500295A (es) | 2017-09-28 |
Family
ID=50478894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201500295A GT201500295A (es) | 2013-03-14 | 2015-09-14 | Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9452139B2 (enExample) |
| EP (1) | EP2968570A1 (enExample) |
| JP (1) | JP6374414B2 (enExample) |
| KR (1) | KR20150129716A (enExample) |
| CN (1) | CN105188757B (enExample) |
| AU (2) | AU2014229265A1 (enExample) |
| BR (1) | BR112015021814A2 (enExample) |
| CA (1) | CA2905615A1 (enExample) |
| CL (1) | CL2015002632A1 (enExample) |
| EA (1) | EA201591729A1 (enExample) |
| GT (1) | GT201500295A (enExample) |
| HK (1) | HK1212616A1 (enExample) |
| IL (1) | IL240963A (enExample) |
| MA (1) | MA38397A1 (enExample) |
| MX (1) | MX2015012814A (enExample) |
| PE (1) | PE20151655A1 (enExample) |
| PH (1) | PH12015501882A1 (enExample) |
| SA (1) | SA515361055B1 (enExample) |
| SG (1) | SG11201506397QA (enExample) |
| TN (1) | TN2015000395A1 (enExample) |
| WO (1) | WO2014141135A1 (enExample) |
| ZA (1) | ZA201505768B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2745977C2 (ru) | 2010-04-22 | 2021-04-05 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| AU2014210942A1 (en) * | 2013-01-31 | 2015-08-20 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| EP3122331A1 (en) * | 2014-03-27 | 2017-02-01 | Novartis AG | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
| SG10201913575VA (en) | 2014-04-15 | 2020-02-27 | Vertex Pharma | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
| US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
| EP3335699A1 (en) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| WO2020247376A1 (en) * | 2019-06-03 | 2020-12-10 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| EP4013245A1 (en) * | 2019-08-15 | 2022-06-22 | Abbott Laboratories | Nutritional powder manufacturing process using micronization, and powder composition |
| CA3175211A1 (en) * | 2020-04-13 | 2021-10-21 | Matthias Emanuel LIECHTI | Lsd dose identification |
| CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
| CN116546980A (zh) * | 2020-12-11 | 2023-08-04 | 江苏恒瑞医药股份有限公司 | 用于肺部递送的药物组合物 |
| CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| EP4387624A4 (en) | 2021-08-19 | 2025-07-30 | Mind Medicine Inc | Immediate Release Formulations of Diethylamide of D-Lysergic Acid for Therapeutical Applications |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| CN116785246A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 一种药物微球及含其的气雾剂 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| WO2025256638A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海济昀生物科技有限公司 | 一种混悬型三联吸入气雾剂组合物及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| ATE137675T1 (de) | 1991-06-26 | 1996-05-15 | Schering Corp | Inhalator für medikamente in pulverform |
| PL173090B1 (pl) | 1992-12-18 | 1998-01-30 | Schering Corp | Inhalator do sproszkowanych lekarstw |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| JP3706136B2 (ja) | 1994-09-21 | 2005-10-12 | ネクター セラピューティクス | 乾燥粉末薬剤の分散装置及び方法 |
| CA2241880A1 (en) | 1996-01-03 | 1997-07-17 | Glaxo Group Limited | Inhalation device |
| SK287878B6 (sk) | 1996-02-21 | 2012-02-03 | Schering Corporation | Powdered medication inhaler |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| DK0937041T3 (da) | 1996-11-11 | 2003-08-11 | Christian R Noe | Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| CA2347856C (en) | 1998-11-13 | 2009-02-17 | Jagotec Ag | Dry powder for inhalation |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| MXPA01012246A (es) | 1999-05-28 | 2002-08-12 | Inhale Therapeutic Syst | Aparato y metodo para distribuir una cantidad medida de medicamento en aerosol. |
| US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
| US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
| WO2001085136A2 (en) | 2000-05-10 | 2001-11-15 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| AU2003287132B2 (en) | 2002-12-13 | 2009-03-12 | Adagit | Pharmaceutical porous particles |
| DK1610850T3 (da) | 2003-04-09 | 2012-06-25 | Novartis Ag | Aerosolapparat med luftindløbsskærm |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| CA2554136C (en) | 2004-02-24 | 2013-05-28 | Microdose Technologies, Inc. | Synthetic jet based medicament delivery method and apparatus |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| BRPI0713951B8 (pt) | 2006-06-30 | 2021-05-25 | Novartis Ag | derivados de quinazolina, e composição farmacêutica |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| RU2463085C2 (ru) | 2006-10-25 | 2012-10-10 | Новартис Аг | Аппарат для распыления порошка, способ его изготовления и применения и его компоненты |
| JP5727927B2 (ja) | 2008-05-15 | 2015-06-03 | ノバルティス アーゲー | フルオロキノロンの肺送達 |
| PL2417106T3 (pl) | 2009-04-09 | 2017-05-31 | Novartis Ag | Sposób wytwarzania soli pirolidyniowych |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| BR112012024059B1 (pt) | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en not_active Ceased
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/en not_active Withdrawn
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Ceased
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968570A1 (en) | 2016-01-20 |
| US20140302147A1 (en) | 2014-10-09 |
| EA201591729A1 (ru) | 2016-05-31 |
| SA515361055B1 (ar) | 2016-11-13 |
| AU2014229265A1 (en) | 2015-09-03 |
| US20160354388A1 (en) | 2016-12-08 |
| CN105188757B (zh) | 2019-04-30 |
| WO2014141135A1 (en) | 2014-09-18 |
| PE20151655A1 (es) | 2015-11-26 |
| JP2016512494A (ja) | 2016-04-28 |
| HK1212616A1 (zh) | 2016-06-17 |
| IL240963A (en) | 2017-05-29 |
| SG11201506397QA (en) | 2015-09-29 |
| CL2015002632A1 (es) | 2016-03-28 |
| KR20150129716A (ko) | 2015-11-20 |
| MA38397A1 (fr) | 2018-01-31 |
| US9452139B2 (en) | 2016-09-27 |
| CN105188757A (zh) | 2015-12-23 |
| TN2015000395A1 (en) | 2017-01-03 |
| JP6374414B2 (ja) | 2018-08-15 |
| MX2015012814A (es) | 2016-02-03 |
| IL240963A0 (en) | 2015-11-30 |
| AU2017203258B2 (en) | 2019-06-20 |
| BR112015021814A2 (pt) | 2017-07-18 |
| CA2905615A1 (en) | 2014-09-18 |
| PH12015501882A1 (en) | 2015-12-07 |
| ZA201505768B (en) | 2017-03-29 |
| AU2017203258A1 (en) | 2017-06-08 |
| US9744178B2 (en) | 2017-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201500295A (es) | Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado | |
| CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
| CL2016000735A1 (es) | Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc. | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| GT201400016A (es) | Indazoles | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CU20160087A7 (es) | Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| BR112016018365A2 (pt) | Formulação farmacêutica aerossol, na forma de um pó seco para distribuição pulmonar, seus usos, forma de dosagem unitária, embalagem ou kit farmacêutico, e dispositivo de distribuição de pó seco | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| PE20150171A1 (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| CL2020001073A1 (es) | Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| SV2016005301A (es) | Nuevos compuestos macrocíclicos | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| CO2017004504A2 (es) | Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| MX2015013254A (es) | Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas. | |
| AR100784A1 (es) | Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador | |
| BR112017003888A2 (pt) | método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico. | |
| BR112014032337A2 (pt) | uso de novos aditivos em uma formulação de tinta incluindo dióxido de titânio como agentes para melhorar a opacidade de filme seco ou de filme que está no processo de secagem | |
| MX2018008348A (es) | Composiciones de inhalador de polvo seco de derivados de 7-azoniabiciclo[2.2.1]heptano. | |
| MX2016002502A (es) | Composiciones farmaceuticas de bendamustina. |